Artiva Biotherapeutics (NASDAQ:ARTV) Insider Subhashis Banerjee Sells 8,222 Shares of Stock

Key Points

• Insider Subhashis Banerjee sold 8,222 Artiva Biotherapeutics shares at an average price of $12.01, for proceeds of approximately $98,746. The transaction reduced his position by 5.47%, leaving him with 142,047 shares.
• Artiva shares recently traded at $11.30, up 1.9%, with the stock significantly above its 52-week low of $2.22. The company reported quarterly EPS of $(0.63), in line with analysts’ expectations.
• Analyst sentiment remains generally positive, with an average “Moderate Buy” rating and a consensus price target of $39.00, while several institutional investors—including 5AM Venture Management, BlackRock, and Citadel Advisors—have recently built or increased positions.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) insider Subhashis Banerjee sold 8,222 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total value of $98,746.22. Following the sale, the insider owned 142,047 shares of the company's stock, valued at approximately $1,705,984.47. This trade represents a 5.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Subhashis Banerjee also recently made the following trade(s):

• On Tuesday, August 18th, Subhashis Banerjee sold 429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $5,148.00.

Artiva Biotherapeutics Trading Up 1.9%

Shares of NASDAQ ARTV traded up $0.21 during midday trading on Monday, hitting $11.30. The company's stock had a trading volume of 249,843 shares, compared to its average volume of 315,106. Artiva Biotherapeutics, Inc. has a 1-year low of $2.22 and a 1-year high of $14.53. The firm's fifty day moving average price is $10.42 and its 200-day moving average price is $8.58.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, hitting the consensus estimate of ($0.63). On average, equities analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. 5AM Venture Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth $22,827,049. Blue Owl Capital Holdings LP bought a new position in Artiva Biotherapeutics during the second quarter worth $8,483,000. Citadel Advisors LLC increased its holdings in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock worth $2,291,000 after purchasing an additional 644,658 shares during the period. BlackRock Inc. acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at about $6,739,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $2,910,000.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ARTV shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Wall Street Zen raised Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. HC Wainwright lifted their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, May 8th. Cantor Fitzgerald restated an "overweight" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source